References
- ETTARO, L. et al.: The economic burden of diabetes, Pharmaeconomics, 2004, 22, p. 149-164
- DOLEŽAL, T. Farmakoekonomické aspekty liečby diabetu, Farmakoekoomika, 2006 3, 1, p.8-12
- GILMER, T. P. et al.: Predictors of health care costs in adults with diabetes, Diabetes care 2005, 28, p. 59-64
- FOLTÁN, V. et al.: Lieky, lieková politika, farmakoekonomika, 1 vydanie, Propact, 2003 186 s
- EISENBERG, J. M.: Clinical economics: a guide to the economic analysis of clinical practices, JAMA, 1989, 262 (20), p.2879-2886
- LILJAS, B.: How to calculate indirect costs in economic evaluations, Pharmacoeconomics, 1997, 13, (1), s. 1-7
- WORLD HEALTH ORGANIZATION. WHOQOL-BREF Introduction, Administration, Scoring and Generic Version of Assessment [online]. Geneva: The WHOQOL Group, 1997, p. 18 www.who.int/entity/mental_health/media/en/76.pdf
- DŽUKA, J. et al. Psychological dimension of quality of life. Prešov: Prešov University, 2004. 519 p.
- ANDEL, M. et al.: A multinational, multicentre, observational, cross sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC SURVEY), Diabetic Medicine 2008, 25 (10), p. 25-31
- TARRIDE JE - HOPKINS R - BLACKHOUSE G. et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics. 2010 Apr 1; 28(4), p. 255-77.
- PALMER, A. J. et al.: The CORE diabetes model: Projecting long term clinical outcomes, costs and cost effectiveness of interventions in diabetes mellitus (types 1 and types 2) to support clinical and reimbursement decision-making, Curr Med Res Opin 2004, 20 (Suppl1):S5-S26
- UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 1998, 352, p. 837-853.
- DRUMMOND M. F. - O BRIEN B. - STODDART G. L, - TORRANCE G. W.: Methods for the economic evaluation of health care programmes, Oxford University press, 2nd edition, 2000, 305 p.
- MASSI-BENEDETTI, M.: The Cost of Diabetes Type II in Europe. The CODE-2 Study. Diabetologia 2002, 45; S1-S4.
- ILAVSKA, A. - GLATZ, P. - HLOSKA, A. - FILKO, M. Economic evaluation of type 2 diabetes, impact of pricing and reimbursement reforms. In: Value in Health 2010. 13, 3, p. A66.
- KAMENSKÝ, G. Costs and benefits of preventive medication intervention in patients with high cardiovascular risk aged between 45 and 64 in Slovakia. Pharmacoeconomics and Drug Policy 2008, 4, 1, p. 11-17.
- SHABAN, A. et al.: The prevalence of depression and anxiety in adults with type 1 diabetes, Diabetic Medicine 2006, 23, p. 445-448
- HRACHOVINOVÁ, T.: Depression and diabetes mellitus: psychosocial factors Available at http://journal.diabetes.org/clinicaldiabetes/v16n21998/PG91.html
- HEISE, T. - PIEBER, T. R.: Towards peakless reproducible and long acting insulins. an assessment of the basal analogues based on isoglycemic clamp studies., Diabetes Obes Metab 2007, 9 (3), p. 290-299